PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($1.68), $0.14 better than the analyst estimate of ($1.82). Revenue for the quarter came in at $116.7 million versus the consensus estimate of $110.5 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.